<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Administration of infliximab: Guidelines for drug administration and the recognition and initial approach to infusion reactions</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Administration of infliximab: Guidelines for drug administration and the recognition and initial approach to infusion reactions</h1>
<div class="graphic"><div class="figure"><div class="ttl">Administration of infliximab: Guidelines for drug administration and the recognition and initial approach to infusion reactions</div><div class="cntnt"><table cellspacing="0"><colgroup span="3" width="33%"></colgroup> <tbody> <tr> <td class="subtitle1_single" colspan="3">Description</td> </tr> <tr class="divider_bottom"> <td colspan="3">Intravenous (IV) administration of infliximab, a tumor necrosis factor-alpha antagonist biologic therapy. Infliximab, a chimeric antibody, is administered in the form of periodic infusions (zero, two, and six weeks and, depending on the subsequent course of the disease, every six to eight weeks thereafter).</td> </tr> <tr> <td class="subtitle2_left" colspan="3">Contraindications to treatment</td> </tr> <tr> <td class="indent1" colspan="3">Known hypersensitivity to the drug or murine proteins</td> </tr> <tr> <td class="indent1" colspan="3">Active systemic or localized infections</td> </tr> <tr> <td class="indent1" colspan="3">History of infection related to a prosthesis that remains in place</td> </tr> <tr> <td class="indent1" colspan="3">Infection with human immunodeficiency virus</td> </tr> <tr> <td class="indent1" colspan="3">Active infection with hepatitis B virus</td> </tr> <tr> <td class="indent1" colspan="3">Congestive heart failure classified on the New York Heart Association scale as functional class III/IV</td> </tr> <tr> <td class="indent1" colspan="3">History of demyelinating disease</td> </tr> <tr> <td class="indent1" colspan="3">History of cancer (except when there has been no recurrence in the preceding five years and in the case of patients with basal cell carcinoma)</td> </tr> <tr> <td class="indent1" colspan="3">Patients with a history of systemic lupus erythematosus</td> </tr> <tr> <td class="indent1" colspan="3">Live vaccines should not be administered during treatment: yellow fever, German measles, measles, polio, or bacillus Calmette-Guérin (BCG)</td> </tr> <tr> <td class="subtitle1_single" colspan="3">Patient care during IV administration of infliximab</td> </tr> <tr> <td class="subtitle2_left" colspan="3">Objectives</td> </tr> <tr> <td class="indent1" colspan="3">To prepare patients physically and psychologically so that they undergo treatment in the best possible conditions</td> </tr> <tr> <td class="indent1" colspan="3">To ensure the patient's safety throughout the infusion process</td> </tr> <tr class="divider_bottom"> <td class="indent1" colspan="3">To prevent treatment-related problems and ensure prompt detection of any such problems</td> </tr> <tr> <td class="subtitle2_left" colspan="3">Preparation of the patient before the procedure</td> </tr> <tr> <td class="indent1" colspan="3">Ascertain what the patient knows about the treatment they are about to receive</td> </tr> <tr> <td class="indent1" colspan="3">Patients may eat breakfast or lunch and take their usual medication unless they have a history of moderate to severe infusion reactions (risk of vomiting)</td> </tr> <tr> <td class="indent1" colspan="3">Make the patient comfortable in a seat or bed, depending on the preference and physical state of each individual</td> </tr> <tr> <td class="indent1" colspan="3">Check whether the patient's chart includes an order for laboratory testing before the procedure, and whether premedication has been prescribed</td> </tr> <tr class="divider_bottom"> <td class="indent1" colspan="3">Personnel: nursing staff</td> </tr> <tr> <td class="subtitle2_left" colspan="3">Procedure</td> </tr> <tr> <td class="indent1" colspan="3">Personnel: nursing staff</td> </tr> <tr class="divider_bottom"> <td class="indent1" colspan="3">Materials:<br/> <ul> <li>Esmarch bandage </li> <li>Cotton </li> <li>Antiseptic </li> <li>20 G catheter </li> <li>Catheter securement dressings </li> <li>Pump </li> <li>Filter (pore size ≤1.2 microns) </li> <li>Infusion pump </li> <li>10 mL syringe </li> <li>21 G needle </li> <li>10 mL of double-distilled water for each vial of infliximab </li> <li>Infliximab (store in refrigerator at between 2 and 8°C) </li> <li>250 mL of 0.9% saline solution </li> </ul> </td> </tr> <tr> <td class="subtitle2_left" colspan="3">Implement laboratory testing order, if any, prior to infusion. Administer prescribed premedication, if any. This can only be diphenhydramine or hydrocortisone.</td> </tr> <tr> <td class="indent1" colspan="3">Check arterial blood pressure, heart rate, respiratory rate, and temperature at the start and after completion of infusion and whenever required by the patient's physical condition</td> </tr> <tr> <td class="sublist2_start" colspan="3">Preparation of the drug</td> </tr> <tr> <td class="sublist2" colspan="3">Aseptic technique</td> </tr> <tr> <td class="sublist2" colspan="3">Reconstitute each 100 mg vial of infliximab with 10 mm of double-distilled water</td> </tr> <tr> <td class="sublist2" colspan="3">Aim the double-distilled water against the side of the vial to prevent foaming</td> </tr> <tr> <td class="sublist2" colspan="3">Ensure that the contents of the vial have dissolved completely, but avoid prolonged and energetic movements</td> </tr> <tr> <td class="sublist2" colspan="3">Allow the solution to stand for five minutes</td> </tr> <tr> <td class="sublist2" colspan="3">The solution should be colorless to slightly yellowish and may contain translucent particles (protein)<br/> <ul> <li>The solution should not be administered if it is inappropriately colored or contains visible opaque particles </li> </ul> </td> </tr> <tr> <td class="sublist2" colspan="3">From the bottle of saline solution, withdraw a volume of saline equal to the volume of infliximab solution to be used in order to obtain a final volume of 250 mL and a concentration of between 0.4 and 4 mg/ml</td> </tr> <tr> <td class="sublist2" colspan="3">The solution must be infused within three hours of reconstitution</td> </tr> <tr> <td class="sublist2" colspan="3">Never dissolve infliximab in dextrose solution</td> </tr> <tr> <td class="sublist2" colspan="3">Cannulate the venous line</td> </tr> <tr> <td class="sublist2" colspan="3">Administer the drug using a volumetric infusion pump<br/> <ul> <li>The first, second, third, and fourth infusions should be administered over two hours (125 mL/hour) </li> <li>Starting with the fifth infusion, the dose can be infused in one hour (250 mL/hour) </li> </ul> </td> </tr> <tr> <td class="indent1" colspan="3">Assess response to treatment; if the patient does not present any anomalous symptoms, he or she can be discharged and return to normal daily activity</td> </tr> <tr class="divider_bottom"> <td class="indent1" colspan="3">Patients must be instructed to telephone their clinician or the nursing staff if they experience any reaction symptoms after the infusion</td> </tr> <tr> <td class="subtitle2_left" colspan="3">Observations</td> </tr> <tr class="divider_bottom"> <td class="indent1" colspan="3">Infusion time can be modified by the clinician responsible for the patient</td> </tr> <tr> <td class="subtitle2_left" colspan="3">Description of problems related to the procedure and remedial action</td> </tr> <tr> <td class="indent1" colspan="3">Acute infusion reactions</td> </tr> <tr> <td class="subtitle3">Mild in the presence of</td> <td class="subtitle3">Moderate in the presence of</td> <td class="subtitle3">Severe in the presence of</td> </tr> <tr class="divider_bottom"> <td class="sublist1"> <ul> <li>Headache </li> <li>Diaphoresis </li> <li>Throat irritation </li> <li>Lumbar pain </li> <li>Hyperemia </li> <li>Nausea </li> <li>Palpitations </li> <li>Itching </li> <li>Cutaneous eruption </li> <li>Flushing </li> <li>Vertigo </li> <li>Vomiting </li> </ul> </td> <td class="sublist1">The same symptoms as mild reactions and <ul> <li>Dysphagia </li> <li>Hypotension or hypertension (± 20 mmHg with respect to baseline) </li> <li>Chest pain or tightness </li> <li>Edema of the face, hands, or lips </li> <li>Suffocating sensation </li> <li>Hyperemia (accompanied by a sensation of heat or fever) </li> <li>Hyperthermia (&lt;39°C) </li> <li>Palpitations, tachycardia </li> <li>Urticaria </li> </ul> </td> <td class="sublist1">The same symptoms as moderate reactions and <ul> <li>Severe hypotension or hypertension (± 40 mmHg with respect to baseline) </li> <li>Hyperthermia and chills (≥39°C) </li> <li>Swelling of the larynx or pharynx with stridor </li> <li>Dyspnea </li> <li>Severe bronchospasm </li> <li>Convulsive seizure </li> <li>Clinically significant chest pain </li> </ul> </td> </tr> <tr> <td class="indent1" colspan="3">Action to be taken:<br/> <ul> <li>Stop the infusion </li> <li>Monitor blood pressure, heart rate, respiratory rate, and temperature </li> <li>Notify the treating clinician </li> <li>If the reaction does not resolve, follow appropriate procedures for management of an acute reaction to infusion of infliximab </li> <li>If extravasation occurs, stop the infusion immediately, notify the treating clinician, attempt to aspirate the extravasated fluid with a 10 to 20 mL syringe, withdraw the IV line, mark the affected area, and follow the hospital's treatment protocol covering such events </li> </ul> </td> </tr> <tr> <td class="subtitle3_left" colspan="3">Important points</td> </tr> <tr> <td class="indent2" colspan="3">To ensure early detection of infusion reactions, monitor the patient's response to treatment</td> </tr> <tr> <td class="indent2" colspan="3">Ensure that the intravenous line is open</td> </tr> <tr> <td class="subtitle3_left" colspan="3">Assessment indicators</td> </tr> <tr> <td class="indent2" colspan="3">The nursing record should include details of the results of vital signs monitoring before and after treatment</td> </tr> <tr> <td class="indent2" colspan="3">The nursing record should provide details of the assessment of tolerance to treatment, that is, the occurrence or absence of incidents</td> </tr> <tr> <td class="subtitle3_left" colspan="3">Records</td> </tr> <tr> <td class="indent2" colspan="3">The following information should be recorded:<br/> <ul> <li>Vital signs </li> <li>The assessment and preparation of the patient prior to treatment </li> <li>Incidents (presence or absence) related to the procedure </li> <li>Assessment of the patient's condition after treatment </li> </ul> </td> </tr> </tbody></table></div><div class="graphic_reference">Original figure modified for this publication. Puig Sanz L, Sáez E, Lozano MJ, et al. [Reactions to infliximab infusions in dermatologic patients: consensus statement and treatment protocol. Working Group of the Grupo Español de Psoriasis de la Academia Española de Dermatología y Venereología.] Actas Dermosifiliogr 2009; 100:103. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id="graphicVersion">Graphic 85654 Version 5.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
